Company Initiates Product Development Program
AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Mirna), a biotechnology company pioneering microRNA replacement therapy for cancer, announced that it is scheduled to present on Monday, January 9th, 2012 at 3:00 pm at Biotech Showcase 2012 in San Francisco. Dr. Paul Lammers, Mirna’s President and Chief Executive Officer, will present a corporate overview, summarizing the key events and accomplishments in 2011 and the 2012 focus, including:
- The completion of an extensive evaluation of external delivery technologies;
- Achieving dramatic preclinical results in a mouse model of hepatocellular carcinoma (HCC);
- Licensing SMARTICLES® liposomal delivery technology from Marina Biotech (Bothell, WA); and
- Receiving therapeutic use claim allowances for numerous potent tumor suppressor microRNAs.
“In 2011, Mirna achieved several major accomplishments in critical areas, including obtaining dramatic preclinical results with MRX01 in an orthotopic mouse model of hepatocellular carcinoma using the SMARTICLES oligonucleotide delivery technology,” said Paul Lammers, M.D., M.Sc., “Now that we have licensed an effective delivery technology, Mirna’s road to the clinic with its potent and proprietary miRNAs is wide open.”
Mirna has initiated a development program targeting liver-based cancers for its lead therapeutic product candidate, MRX01. MRX01 is the proprietary tumor suppressor microRNA, miR-34, formulated with SMARTICLES lipid nanoparticles. This formulation will enter IND-enabling studies with the goal of filing an IND in Q4 of 2012 and the initiation of a Phase 1 clinical trial in early 2013. Mirna has assembled a world-class scientific advisory board to assist in the design and conduct of these studies. It is worthwhile to note that the SMARTICLES technology has been included in at least one product that has successfully entered human clinical trials.
About Biotech Showcase™
Biotech Showcase™ is a forum devoted to providing biotechnology companies, investors and pharmaceutical executives with an opportunity to meet in one place during the course of one of the world's largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.
Now in its fourth year, this rapidly growing financial-focused biotech conference features multiple tracks of presenting companies, plenary sessions, an opportunity to schedule one-to-one partnering meetings and networking. The attendees to the showcase include private and public equity investors, analysts, bankers, biopharmaceutical industry executives and other industry professionals. The event is being held at the Parc 55 Wyndham San Francisco – Union Square.
microRNAs (or miRNAs) are approximately 20-25 nucleotides in length and affect gene expression by interacting with messenger RNAs. Unlike siRNAs, miRNAs are encoded in the human genome and are used as natural regulators of gene expression. More than 1,400 miRNAs are encoded in the human genome and comprise approximately 2% of all mammalian genes. Since each miRNA appears to regulate the expression of tens to hundreds of different genes, miRNAs can function as “master-switches,” efficiently regulating and coordinating multiple cellular pathways and processes. By coordinating the expression of multiple genes, miRNAs are responsible for guiding proper embryonic development, immunity and inflammation, as well as cellular growth and proliferation. Misregulation of miRNAs appears to play a fundamental role in the occurrence, growth and dissemination of many cancers, and replacement of down regulated miRNAs in tumor cells results in a positive therapeutic response.
About Mirna Therapeutics
Mirna Therapeutics is a biotechnology company focused on the development and commercialization of microRNA (miRNA) therapeutics. The Company has a foundational intellectual property portfolio on the therapeutic use of miRNAs developed by its own scientists as well as in-licensed from other institutions. Mirna’s IP portfolio contains >300 miRNAs with applications in oncology and other diseases. Oncology-directed miRNAs include those that are key tumor suppressors in cancer, such as miR-34 and let-7 that have been shown to block tumor growth in a number of different pre-clinical animal studies. The Company, founded in 2007 and located in Austin, Texas, has received significant funding from the State of Texas, both through the State’s Emerging Technology Fund and from the Cancer Prevention and Research Institute of Texas (CPRIT). Mirna Therapeutics is the recipient of a $10.3 million commercialization award from CPRIT. For more information, visit www.mirnarx.com.
Mirna Therapeutics, Inc.
Paul Lammers, M.D., M.Sc., 512-901-0900
KEYWORDS: United States North America California Texas
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology